Stock Detail
DURECT CORPORATION
Drug Manufacturers Other
DRRX @ Yahoo Finance | DRRX Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $1.38 | $1.50 | $-0.06 | -4.17% | 0.00 | $1.44 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $1.42 | $1.36 | 220,141 | 120.68M | 397,381 | -5.52 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 1.55 | 1.46 | 1.41 | 1.32 | 1.27 |
Stock Profile
DURECT Corporation develops pharmaceutical systems based on its proprietary drug delivery technology platforms. It has various product candidates under development in the areas of pain, and other chronic diseases and disorders. Its primary product candidates in development include SABER-Bupivacaine, TRANSDUR-Sufentanil, ORADUR- Oxycodone, DURIN-Leuprolide, and CHRONOGESIC. SABER-Bupivacaine, a post-operative pain relief depot product candidate, is a sustained release injectible using DURECT's SABER delivery system to deliver bupivacaine. TRANSDUR-Sufentanil, a transdermal sufentanil product candidate in phase II clinical studies, uses the TRANSDUR delivery system to deliver sufentanil, an opioid medication, to provide chronic pain relief for up to seven days. ORADUR- Oxycodone, an oral opioid product in phase III clinical studies, would be used to decrease the potential for oxycodone abuse. DURIN-Leuprolide is a product candidate using the DURIN implant system to deliver the peptide leuprolide to treat Alzheimer's disease. The CHRONOGESIC Pain Therapy System is an osmotic implant that would deliver sufentanil for an extended duration. CHRONOGESIC would be used to treat chronic pain and is based on the DUROS System, an osmotic pump. DURECT also engages in the research and development pharmaceutical systems in various therapeutic areas, including chronic pain, central nervous system disorders, and cardiovascular disease. In addition, the company manufactures and sells osmotic pumps used for animal research, and various biodegradable polymers for pharmaceutical and medical device clients for use as raw materials in their products. DURECT has strategic partnerships with Pain Therapeutics, Inc.; Voyager Pharmaceutical Corporation; Endo Pharmaceuticals, Inc.; Endo Pharmaceuticals, Inc.; and NeuroSystec Corporation. The company was co-founded by Felix Theeuwes, James E. Brown, and Thomas A. Schreck in 1998. DURECT is headquartered in Cupertino, California.